with acute myocardial infarction as determined by optical coherence tomography. Am J Cardiol. 2010; 105:318–22.
144 144 Fujii K, Kawasaki D, Masutani M, et al. OCT assessment of thin‐cap fibroatheroma distribution in native coronary arteries. JACC Cardiovasc Imaging. 2010; 3:168–75.
145 145 Uemura S, Ishigami K, Soeda T,et al. Thin‐cap fibroatheroma and microchannel findings in optical coherence tomography correlate with subsequent progression of coronary atheromatous plaques. Eur Heart J. 2012; 33:78–85.
146 146 Takarada S, Imanishi T, Kubo T, et al. Effect of statin therapy on coronary fibrous‐cap thickness in patients with acute coronary syndrome: assessment by optical coherence tomography study. Atherosclerosis. 2009; 202:491–7.
147 147 Komukai K, Kubo T, Kitabata H, et al. Effect of atorvastatin therapy on fibrous cap thickness in coronary atherosclerotic plaque as assessed by optical coherence tomography: the EASY‐FIT study. J Am Coll Cardiol. 2014; 64:2207–17.
148 148 Fuster V. Lewis A. Conner Memorial Lecture. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation. 1994; 90:2126–46.
149 149 Lendon CL, Davies MJ, Born GV, Richardson PD. Atherosclerotic plaque caps are locally weakened when macrophages density is increased. Atherosclerosis. 1991; 87:87–90.
150 150 Moreno PR, Falk E, Palacios IF, et al. Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. Circulation. 1994; 90:775–8.
151 151 Tearney GJ, Yabushita H, Houser SL, et al. Quantification of macrophage content in atherosclerotic plaques by optical coherence tomography. Circulation. 2003; 107:113–9.
152 152 Raffel OC, Tearney GJ, Gauthier DD, et al. Relationship between a systemic inflammatory marker, plaque inflammation, and plaque characteristics determined by intravascular optical coherence tomography. Arterioscler Thromb Vasc Biol. 2007; 27:1820–7.
153 153 Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010; 464:1357–61.
154 154 Abela GS, Aziz K, Vedre A, et al. Effect of cholesterol crystals on plaques and intima in arteries of patients with acute coronary and cerebrovascular syndromes. Am J Cardiol. 2009; 103:959–68.
155 155 Abela GS, Aziz K. Cholesterol crystals cause mechanical damage to biological membranes: a proposed mechanism of plaque rupture and erosion leading to arterial thrombosis. Clin Cardiol. 2005; 28:413–20.
156 156 Kataoka Y, Puri R, Hammadah M, et al. Cholesterol crystals associate with coronary plaque vulnerability in vivo. J Am Coll Cardiol. 2015; 65:630–2.
157 157 Dai J, Tian J, Hou J, et al. Association between cholesterol crystals and culprit lesion vulnerability in patients with acute coronary syndrome: An optical coherence tomography study. Atherosclerosis. 2016; 247:111–7.
158 158 Barger AC, Beeuwkes R, 3rd. Rupture of coronary vasa vasorum as a trigger of acute myocardial infarction. Am J Cardiol. 1990; 66:41G–43G.
159 159 Tenaglia AN, Peters KG, Sketch MH, Jr. Annex BH. Neovascularization in atherectomy specimens from patients with unstable angina: implications for pathogenesis of unstable angina. Am Heart J. 1998; 135:10–4.
160 160 Kitabata H, Tanaka A, Kubo T, et al. Relation of microchannel structure identified by optical coherence tomography to plaque vulnerability in patients with coronary artery disease. Am J Cardiol. 2010; 105:1673–8.
161 161 Caplan JD, Waxman S, Nesto RW, Muller JE. Near‐infrared spectroscopy for the detection of vulnerable coronary artery plaques. J Am Coll Cardiol. 2006; 47:C92–6.
162 162 Moreno PR, Lodder RA, Purushothaman KR, et al. Detection of lipid pool, thin fibrous cap, and inflammatory cells in human aortic atherosclerotic plaques by near‐infrared spectroscopy. Circulation. 2002; 105:923–7.
163 163 Puri R, Madder RD, Madden SP, et al. Near‐Infrared Spectroscopy Enhances Intravascular Ultrasound Assessment of Vulnerable Coronary Plaque: A Combined Pathological and in vivo Study. Arterioscler Thromb Vasc Biol. 2015; 35:2423–31.
164 164 Madder RD, Smith JL, Dixon SR, Goldstein JA. Composition of target lesions by near‐infrared spectroscopy in patients with acute coronary syndrome versus stable angina. Circ Cardiovasc Interv. 2012; 5:55–61.
165 165 Madder RD, Goldstein JA, Madden SP, et al. Detection by near‐infrared spectroscopy of large lipid core plaques at culprit sites in patients with acute ST‐segment elevation myocardial infarction. JACC Cardiovasc Interv. 2013; 6:838–46.
166 166 Madder RD, Husaini M, Davis AT, et al. Detection by near‐infrared spectroscopy of large lipid cores at culprit sites in patients with non‐ST‐segment elevation myocardial infarction and unstable angina. Catheter Cardiovasc Interv. 2015; 86:1014–21.
167 167 Kini AS, Baber U, Kovacic JC, et al. Changes in plaque lipid content after short‐term intensive versus standard statin therapy: the YELLOW trial (reduction in yellow plaque by aggressive lipid‐lowering therapy). J Am Coll Cardiol. 2013; 62:21–29.
168 168 Oemrawsingh RM, Cheng JM, Garcia‐Garcia HM, et al. Near‐infrared spectroscopy predicts cardiovascular outcome in patients with coronary artery disease. J Am Coll Cardiol. 2014; 64:2510–8.
169 169 Kini AS, Baber U, Kovacic JC, et al. Changes in plaque lipid content after short‐term intensive versus standard statin therapy: the YELLOW trial (reduction in yellow plaque by aggressive lipid‐lowering therapy). J Am Coll Cardiol. 2013; 62:21–9.
170 170 Oemrawsingh RM, Garcia‐Garcia HM, van Geuns RJ, et al. Integrated Biomarker and Imaging Study 3 (IBIS‐3) to assess the ability of rosuvastatin to decrease necrotic core in coronary arteries. EuroIntervention. 2016; 12:734–9.
171 171. Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation. 2003; 108:1772–8.
172 172 Ross R. Atherosclerosis‐‐an inflammatory disease. N Engl J Med. 1999; 340:115–26.
173 173 Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation. 2006; 113:2335–62.
174 174 Creemers EE, Tijsen AJ, Pinto YM. Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease? Circulation research. 2012; 110:483–495.
175 175 Fuster V, Fayad ZA, Moreno PR, et al. Atherothrombosis and high‐risk plaque: Part II: approaches by noninvasive computed tomographic/magnetic resonance imaging. J Am Coll Cardiol. 2005; 46:1209–18.
176 176 Fuster V, Moreno PR, Fayad ZA, et al. Atherothrombosis and high‐risk plaque: part I: evolving concepts. J Am Coll Cardiol. 2005; 46:937–54.
177 177 Tsimikas S, Willerson JT and Ridker PM. C‐reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. J Am Coll Cardiol. 2006; 47:C19–31.
178 178 Wang G‐K, Zhu J‐Q, Zhang J‐T, et al. Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J. 2010; 31:659–666.
179 179 D'Alessandra Y, Devanna P, Limana F, et al. Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. Eur Heart J. 2010; 31:2765–2773.
180 180 Tijsen AJ, Creemers EE, Moerland PD, et al. MiR423‐5p as a circulating biomarker for heart failure. Circulation Research. 2010; 106:1035.
181 181 Fichtlscherer S, De Rosa S, Fox H, et al. Circulating microRNAs in patients with coronary artery disease. Circulation Research. 2010; 107:677–684.
182 182 Li S, Zhu J, Zhang W, et al. Signature microRNA expression profile of essential hypertension and its novel link to human cytomegalovirus infection. Circulation. 2011; 124:175–184.
183 183 Zampetaki A, Kiechl S, Drozdov I, et al. Plasma microRNA profiling reveals loss of endothelial miR‐126 and other microRNAs in type 2 diabetes. Circulation Research. 2010; 107:810–817.
184 184